Aneurysmal subarachnoid hemorrhage occurring during sleep: Clinical characteristics and risk factors

• Published in: Journal of stroke and cerebrovascular diseases 2024-04, Vol.33 (4), p.107591-107591, Article 107591
• Main Authors: Inamasu, Joji, Akiyama, Takenori, Akaji, Kazunori, Inaba, Makoto, Nishimoto, Masaaki, Kojima, Atsuhiro, Terao, Satoshi, Hayashi, Takuro, Mizutani, Katsuhiro, Toda, Masahiro
• Format: Article
• Language: English
• Subjects: Aneurysmal subarachnoid hemorrhage; Antiplatelet; Diabetes; Diabetes Mellitus - diagnosis; Diabetes Mellitus - epidemiology; Humans; Retrospective Studies; Risk Factors; Sleep; Subarachnoid Hemorrhage - diagnostic imaging; Subarachnoid Hemorrhage - epidemiology; Subarachnoid Hemorrhage - etiology
• ISSN: 1052-3057; 1532-8511
• DOI: 10.1016/j.jstrokecerebrovasdis.2024.107591

Aneurysmal subarachnoid hemorrhage (aSAH) is known to be triggered by several specific human activities. Sleep, by contrast, has not been considered a triggering activity for aSAH, and clinical characteristics of patients who sustain aSAH during sleep have rarely been reported in the literature. This is a retrospective analysis on the data acquired through a multicenter aSAH registry. Between January 2019 and December 2021, a total of 732 aSAH patients had been registered into our database. After excluding 109 patients whose activities at aSAH onset had been unidentifiable, the remaining 623 aSAH patients were dichotomized to 59 patients who sustained aSAH during sleep (Sleep group) and 564 patients who sustained aSAH during daytime activities (Awake group). Two-group comparison of demographic variables and multivariate logistic regression analysis were performed to clarify their clinical characteristics and identify potential risk factors. The Sleep group exhibited significantly higher frequencies of diabetes (15.5 % vs. 6.4 %, p = 0.01) and antiplatelet use (13.8 % vs. 4.6 %, p=0.004) than the Awake group. Furthermore, multivariate logistic regression analysis showed that diabetes (OR, 3.051; 95 % CI, 1.281-7.268; p = 0.012) and antiplatelet use (OR, 3.640; 95 % CI, 1.422-9.316; p = 0.007) were correlated with aSAH occurring during sleep. There were no significant inter-group differences in the patient outcomes evaluated at discharge. The current results indicate that risk factors may exist for aSAH occurring during sleep. Further investigations on how comorbidities such as diabetes, antiplatelet use and sleep apnea affect human hemodynamic and hemostatic parameters during sleep is warranted to better understand those relationships.